Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 645-651

  Laschak, Martin ^a   Bechtel, Marina ^a,b   Spindler, Klaus Dieter ^a   Hessenauer, Andrea ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Androgen receptor; Co repressor; NCoR; Prostate cancer; SMRT

Indexed keywords

ANDROGEN RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; MALE; NUCLEAR RECEPTOR CO-REPRESSOR 2; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 79960816839     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.735     Document Type: Article

References (29)

1. Rinnab L, Hessenauer A, Schutz SV, Schmid E, Kufer R, Finter F, Hautmann RE, Spindler KD and Cronauer MV: Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches. Urologe A 47: 314-325, 2008 (In German).
2. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H and Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55: 3068-3072, 1995.
3. Feldman BJ and Feldman D: The development of androgenin-dependent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
4. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS and Wilson EM: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319, 2001. (Pubitemid 32685750)
5. Culig Z, Comuzzi B, Steiner H, Bartsch G and Hobisch A: Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 92: 265-271, 2004. (Pubitemid 40128247)
6. Chmelar R, Buchanan G, Need EF, Tilley W and Greenberg NM: Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 120: 719-733, 2007. (Pubitemid 46175390)
7. Wang C, Hsu L and Chang C: Androgen receptor corepressors: an overview. Prostate 63: 117-130, 2005.
8. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL and Parker MG: Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 25: 1425-1436, 2005. (Pubitemid 40204919)
9. Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, Reebye V, Varela-Carver A, Kawano Y, Waxman J and Bevan CL: Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene 26: 1757-1768, 2007. (Pubitemid 46426196)
10. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, Lam EW and Bevan CL: Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 23: 2996-3004, 2004. (Pubitemid 38648190)
11. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, Giebel J, Scharf C, Woenckhaus C, Dombrowski F and Walther R: Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266: 171-185, 2008.
12. Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM and Campbell MJ: Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 23: 6712-6725, 2004. (Pubitemid 39280003)
13. Ting HJ, Bao BY, Reeder JE, Messing EM and Lee YF: Increased expression of corepressors in aggressive androgenin-dependent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 5: 967-980, 2007. (Pubitemid 47416673)
14. Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J and Wong J: Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J 19: 4342-4350, 2000. (Pubitemid 30623745)
15. Goodson M, Jonas BA and Privalsky MA: Corepressors: custom tailoring and alterations while you wait. Nucl Recept Signal 3: e003, 2005.
16. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H and Chen JD: Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278: 5052-5061, 2003. (Pubitemid 36801015)
17. Agoulnik IU, Krause WC, Bingman WE, Rahman HT, Amrikachi M, Ayala GE and Weigel NL: Repressors of androgen and progesterone receptor action. J Biol Chem 278: 31136-31148, 2003. (Pubitemid 36994629)
18. Cheng S, Brzostek S, Lee SR, Hollenberg AN and Balk SP: Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 16: 1492-1501, 2002. (Pubitemid 34743669)
19. Jonas BA and Privalsky ML: SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem 279: 54676-54686, 2004. (Pubitemid 40053211)
20. Tiefenbach J, Novac N, Ducasse M, Eck M, Melchior F and Heinzel T: SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Mol Biol Cell 17: 1643-1651, 2006. (Pubitemid 44011582)
21. Peters I, Weidemann W, Romalo G, Knorr D, Schweikert HU and Spindler KD: An androgen receptor mutation in the direct vicinity of the proposed C-terminal alpha-helix of the ligand binding domain containing the AF-2 transcriptional activating function core is associated with complete androgen insensitivity. Mol Cell Endocrinol 148: 47-53, 1999.
22. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J, Sies H, Ackermann R and Kroncke KD: Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26: 1875-1884, 2007. (Pubitemid 46474631)
23. Schneider CC, Hessenauer A, Montenarh M and Gotz C: p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. Prostate 70: 126-134, 2010.
24. Peterson TJ, Karmakar S, Pace MC, Gao T and Smith CL: The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Mol Cell Biol 27: 5933-5948, 2007. (Pubitemid 47333769)
25. Karmakar S, Gao T, Pace MC, Oesterreich S and Smith CL: Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor. Mol Endocrinol 24: 1187-1202, 2010.
26. Li X, Kimbrel EA, Kenan DJ and McDonnell DP: Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation. Mol Endocrinol 16: 1482-1491, 2002. (Pubitemid 34743668)
27. Varlakhanova N, Snyder C, Jose S, Hahm JB and Privalsky ML: Estrogen receptors recruit SMRT and N-CoR corepressors through newly recognized contacts between the corepressor N terminus and the receptor DNA binding domain. Mol Cell Biol 30: 1434-1445, 2010.
28. Ordentlich P, Downes M, Xie W, Genin A, Spinner NB and Evans RM: Unique forms of human and mouse nuclear receptor corepressor SMRT. Proc Natl Acad Sci USA 96: 2639-2644, 1999. (Pubitemid 29148770)
29. Cote S, McNamara S, Brambilla D, Bianchini A, Rizzo G, del Rincon SV, Grignani F, Nervi C and Miller Jr WH: Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors. Blood 104: 4226-4235, 2004. (Pubitemid 39620177)